Navigation Links
Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Date:7/14/2008

a meeting with the FDA to discuss potentially initiating a Phase III clinical trial program for INS-19. The Company also intends to initiate human bioequivalence clinical studies for INS-20 in the fourth quarter of 2008, with data expected in the first quarter of 2009. Insmed has several other FOB products which are currently at an earlier stage of cell line development and product characterisation.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock coul
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... release its non-invasive hydration monitoring wearable early 2016. , The device, called ... using proprietary optical and electrical sensing technology. These sensors track trending interstitial ...
(Date:9/2/2015)... (PRWEB) , ... September 02, ... ... provider of regulatory compliance, quality systems, analytical testing, education and consulting services ... with expertise in medical device products/processes development, design control, validation, quality assurance ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... botanical and plant-derived compounds. BCC Research reveals in its new report that ... this market defines the category and generates the most market demand. , ...
Breaking Biology Technology:Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... MedImmune announced today it,will present four abstracts ... Conference & Exhibition that add to the company,s ... syncytial virus (RSV),a leading cause of viral respiratory ... data that further demonstrate the burden of RSV ...
... Inc. (NTI(R)) (Nasdaq: NTII ), today announced it ... provide an update on the,Viprinex(TM) (ancrod) Phase 3 Trial ... Paul E. Freiman, president and chief executive,officer and Warren ... Monday, October 13, 2008 -- Time: 1:00 ...
... 10 CSMG,Technologies, Inc., (OTC Bulletin Board: ... has received approval of its fifth U.S.,patent. ... application for "Bonding of,Soft Biological Tissues by ... Technologies subsidiary Live Tissue Connects ("LTC"),platform tissue ...
Cached Biology Technology:MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 2MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 3MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 4MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 5Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 3
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... and editors of the Pensoft journal ZooKeys carried ... (84 %) are willing to publish their data, so that ... integrate with other data" said Dr Lyubomir Penev, managing director ... data, the scientists mentioned that "open data increases ...
... Jerusalem 31 May 2011 - Parliamentarians ... the Knesset (parliament) today for the 17th EUREKA ... a growth in market-oriented R&D projects and to ... by Knesset Science and Technology Committee head Meir ...
... research raises the possibility that the critically short supply ... treating so-called "marginal" livers with a substance that protects ... supplies. The report appears in ACS, journal Molecular ... the need for liver transplants has grown over the ...
Cached Biology News:Data publishing policies and guidelines for biodiversity data by Pensoft 2
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
... pass sequencing of plasmids and PCR ... our high performance sequencing pipeline which ... per day. The key benefits we ... are rapid turnaround, high sequencing pass ...
... high quality whole genome sequencing service. Our ... allow even the smallest of laboratories to ... features which set our whole genome sequencing ... strategies, proprietary assembly software, rapid project turnaround ...
Shotgun library construction and high-throughput DNA sequencing of microbial genomes, BACs, adenoviruses, phosmids and cosmids. LIMS tracking utilizing Geospiza's Finch system....
Biology Products: